We generally don’t know what stocks Warren Buffett and the rest of Berkshire Hathaway’s (NYSE:BRK-A) (NYSE:BRK-B) stock-picking team are buying until the company’s 13-F is released. However, Buffett confirmed in a recent interview that he has bought two stocks in particular since the second quarter ended.
Specifically, Berkshire’s Apple (NASDAQ:AAPL) stake has gotten even larger, and the company has started buying back its own stock for the first time in years. Here’s a rundown of what we know, why Buffett could be making these moves, and whether investors should follow Buffett’s lead and invest in these two companies.
Image Source: Getty Images.
Even more Apple
Tech giant and iPhone maker Apple is already the largest stock position in Berkshire Hathaway’s portfolio by a wide margin. As of the end of the second quarter, Berkshire owned nearly 252 million shares of Apple, which translates to more than 5% of the trillion-dollar company and is worth about $56.7 billion at the current share price.
Best Warren Buffett Stocks To Watch For 2019: MutualFirst Financial Inc.(MFSF)
Advisors’ Opinion:
- [By Ethan Ryder]
Media coverage about MutualFirst Financial (NASDAQ:MFSF) has trended somewhat negative recently, Accern Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. MutualFirst Financial earned a news impact score of -0.01 on Accern’s scale. Accern also assigned news articles about the bank an impact score of 47.9474560000459 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
- [By Stephan Byrd]
Get a free copy of the Zacks research report on MutualFirst Financial (MFSF)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Max Byerly]
Get a free copy of the Zacks research report on MutualFirst Financial (MFSF)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Logan Wallace]
MutualFirst Financial, Inc. (NASDAQ:MFSF) – Stock analysts at DA Davidson increased their Q3 2018 earnings per share (EPS) estimates for shares of MutualFirst Financial in a research report issued to clients and investors on Monday, July 30th. DA Davidson analyst K. Reevey now forecasts that the bank will earn $0.68 per share for the quarter, up from their previous forecast of $0.62. DA Davidson has a “Neutral” rating on the stock. DA Davidson also issued estimates for MutualFirst Financial’s Q4 2018 earnings at $0.69 EPS, FY2018 earnings at $2.55 EPS and FY2019 earnings at $2.79 EPS.
Best Warren Buffett Stocks To Watch For 2019: Corbus Pharmaceuticals Holdings, Inc.(CRBP)
Advisors’ Opinion:
- [By Keith Speights]
Three of the biggest winners this week were Viking Therapeutics (NASDAQ:VKTX), Acadia Pharmaceuticals (NASDAQ:ACAD), and Corbus Pharmaceuticals (NASDAQ:CRBP). What drove these biotech stocks higher — and are they buys now?
- [By Keith Speights]
Biotech
GW Pharmaceuticals (NASDAQ:GWPH) $3.7 billion
Cara Therapeutics (NASDAQ: CARA) $697 million
Insys Therapeutics (NASDAQ: INSY) $473 million
22nd Century Group (NYSEMKT: XXII) $313 million
Corbus Pharmaceuticals (NASDAQ: CRBP) $271 millionAncillary provider
- [By Sean Williams]
Among drug developers, none had a more disappointing quarter than small-cap, clinical-stage company Corbus Pharmaceuticals (NASDAQ:CRBP), which fell more than 17%. Corbus is associated with the marijuana industry through its lead drug lenabasum (formerly anabasum), which is an oral endocannabinoid-mimetic drug that binds with naturally occurring CB2 receptors expressed on fibroblasts and immune cells. In particular, lenabasum is being targeted at four indications: systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.
Best Warren Buffett Stocks To Watch For 2019: RadiSys Corporation(RSYS)
Advisors’ Opinion:
- [By Logan Wallace]
RadiSys (NASDAQ: RSYS) and Fortinet (NASDAQ:FTNT) are both computer and technology companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, earnings, institutional ownership, analyst recommendations and dividends.
- [By Joseph Griffin]
RadiSys (NASDAQ: RSYS) and Stratasys (NASDAQ:SSYS) are both small-cap computer and technology companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.
- [By Shane Hupp]
Get a free copy of the Zacks research report on RadiSys (RSYS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Best Warren Buffett Stocks To Watch For 2019: Innoviva, Inc. (INVA)
Advisors’ Opinion:
- [By Sean Williams, Chuck Saletta, and Brian Feroldi]
With this in mind, we asked three Motley Fool investors to name one healthcare stock that’s tops on their list for the month of June. These three mid-cap stocks made the cut: royalty drug company Innoviva (NASDAQ:INVA), mental illness treatment center operator Acadia Healthcare (NASDAQ:ACHC), and health savings account provider HealthEquity (NASDAQ:HQY).
- [By Ethan Ryder]
Get a free copy of the Zacks research report on Innoviva (INVA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Max Byerly]
Virginia Retirement Systems ET AL lifted its holdings in shares of Innoviva Inc (NASDAQ:INVA) by 67.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 145,100 shares of the biotechnology company’s stock after acquiring an additional 58,700 shares during the period. Virginia Retirement Systems ET AL’s holdings in Innoviva were worth $2,002,000 at the end of the most recent reporting period.
Best Warren Buffett Stocks To Watch For 2019: Heron Therapeutics, Inc. (HRTX)
Advisors’ Opinion:
- [By Jason Hall, George Budwell, and Chuck Saletta]
And while it may not always work out well to simply copy the moves other investors make, it can pay off to use their buying and selling moves as jumping-off points in your own research. We asked three real-world investors for their insight, and they wrote about two recent Buffett buys of Apple Inc. (NASDAQ:AAPL) and USG Corporation (NYSE:USG), and a recent Baker Brothers buy of Heron Therapeutics Inc (NASDAQ:HRTX).
- [By Max Byerly]
Heron Therapeutics Inc (NASDAQ:HRTX) – Equities researchers at Cantor Fitzgerald issued their FY2019 earnings per share (EPS) estimates for shares of Heron Therapeutics in a report issued on Thursday, July 19th. Cantor Fitzgerald analyst L. Chen anticipates that the biotechnology company will post earnings of ($0.23) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $50.00 price objective on the stock.
- [By Joseph Griffin]
Shares of Heron Therapeutics Inc (NASDAQ:HRTX) dropped 0.2% on Thursday . The stock traded as low as $29.30 and last traded at $30.95. Approximately 33,849 shares traded hands during trading, a decline of 96% from the average daily volume of 944,129 shares. The stock had previously closed at $31.00.
- [By George Budwell]
Shares of the commercial-stage biotech Heron Therapeutics (NASDAQ:HRTX) gained as much as 36.3% today on abnormally high volume. What triggered this massive surge higher?
- [By George Budwell]
As things stand now, Cara’s immediate future hinges directly on the strength of Korsuva’s late-stage results in both postoperative pain and CKD-associated pruritus. Having said that, I think investors should largely consider the drug’s postoperative pain indication as icing on the cake at this point. Heron Therapeutics’ (NASDAQ:HRTX)experimental pain medicine HTX-011, after all, appears to have a sizable advantage in terms of efficacy over Korsuva based on the trial data so far. And Heron is almost certainly going to beat Cara to market by several years as well, giving it a formidable first-mover advantage.